New Drug Shows Promise Against Advanced Pancreatic Cancer

An experimental pill, daraxonrasib, has demonstrated a significant increase in survival time for patients with advanced RAS-mutated pancreatic cancer. This development, presented at a major oncology meeting, offers a notable advancement in treating a particularly aggressive form of cancer. The drug functions by targeting and deactivating the KRAS protein.